<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        318-212-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CO-VALISTA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        320,25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        41.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Co-Valista film-coated tablets contain two active substances called valsartan and hydrochlorothiazide. Both of these substances help to control high blood pressure (hypertension).</p><p>● Valsartan belongs to a class of medicines known as &ldquo;angiotensin II receptor antagonists&rdquo;, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. Valsartan works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.</p><p>● Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics (also known as &ldquo;water tablets&rdquo;). Hydrochlorothiazide increases urine output, which also lowers blood pressure.</p><p>Co-Valista is used to treat high blood pressure which is not adequately controlled by a single substance alone.</p><p>High blood pressure increases the workload of the heart and arteries. If not treated, it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Co-Valista :</strong></p><p>● if you are allergic to valsartan, hydrochlorothiazide, sulphonamide derivatives (substances chemically related to hydrochlorothiazide) soya oil, peanut oil or to any of the other ingredients of this medicine (listed in section 6).</p><p>● if you are <strong>more than 3 months pregnant </strong>(it is also better to avoid Co-Valista in early pregnancy - see pregnancy section).</p><p>● if you have severe liver disease.</p><p>● if you have severe kidney disease.</p><p>● if you are unable to urinate.</p><p>● if you are treated with an artificial kidney.</p><p>● if the level of potassium or sodium in your blood is lower than normal, or if the level of calcium in your blood is higher than normal despite treatment.</p><p>● if you have gout.</p><p><strong>If any of the above apply to you, do not take this medicine and speak to your doctor.</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Co-Valista , especially:</p><p>● if you are taking potassium-sparing medicines, potassium supplements, salt substitutes containing potassium or other medicines that increase the amount of potassium in your blood such as heparin. Your doctor may need to check the amount of potassium in your blood regularly.</p><p>● if you have low levels of potassium in your blood.</p><p>● if you have diarrhoea or severe vomiting.</p><p>● if you are taking high doses of water tablets (diuretics).</p><p>● if you have severe heart disease.</p><p>● if you suffer from a narrowing of the kidney artery.</p><p>● if you have recently received a new kidney.</p><p>● if you suffer from hyperaldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of Co-Valista is not recommended.</p><p>● if you have liver or kidney disease.</p><p>● if you have fever, rash and joint pain, which may be signs of systemic lupus erythematosus (SLE, a so-called autoimmune disease).</p><p>● if you have diabetes, gout, high levels of cholesterol or fats in your blood.</p><p>● if you have had allergic reactions with the use of other blood pressure-lowering agents of this class (angiotensin II receptor antagonists) or if you have allergy or asthma.</p><p>● it may cause increased sensitivity of the skin to sun.</p><p><strong>Children and adolescents</strong></p><p>The use of Co-Valista in children and adolescents (below the age of 18 years) is not recommended.</p><p>You must tell your doctor if you think you are (or might become) pregnant. Co-Valista is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p><strong>Other medicines and Co-Valista</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>The effect of the treatment can be influenced if Co-Valista is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines.</p><p>This especially applies to the following medicines:</p><p>● lithium, a medicine used to treat some types of psychiatric illness</p><p>● medicines that affect or can be affected by potassium blood levels, such as digoxin, a medicine to control the heart rhythm, some antipsychotic medicines</p><p>● medicines that may increase the amount of potassium in your blood, such as potassium supplements, potassium-containing salt substitutes, potassium sparing medicines, heparin</p><p>● medicines that may reduce the amount of potassium in your blood, such as corticosteroids, some laxatives</p><p>● diuretics (water tablets), medicines for the treatment of gout, such as allopurinol, therapeutic vitamin D and calcium supplements, medicines for the treatment of diabetes (oral agents or insulins)</p><p>● other medicines to lower your blood pressure, such as beta blockers or methyldopa, or medicines that tighten your blood vessels or stimulate your heart, such as noradrenaline or adrenaline</p><p>● medicines to increase blood sugar levels, such as diazoxide</p><p>● medicines to treat cancer, such as methotrexate or cyclophosphamide</p><p>● pain killers</p><p>● arthritis medicines</p><p>● muscle relaxing medicines, such as tubocurarine</p><p>● anti-cholinergic medicines, such as atropine or biperiden</p><p>● amantadine (a medicine used to prevent influenza)</p><p>● cholestyramine and colestipol (medicines used to treat high levels of fats in the blood)</p><p>● ciclosporin, a medicine used for organ transplant to avoid organ rejection</p><p>● some antibiotics (tetracyclines), anaesthetics and sedatives</p><p>● carbamazepine, a medicine used to treat seizure conditions</p><p>&nbsp;</p><p><strong>Co-Valista with food and alcohol</strong></p><p>You can take Co-Valista with or without food. Avoid taking alcohol until you have talked to your doctor. Alcohol may make your blood pressure fall more and/or increase the risk of you becoming dizzy or feeling faint.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>● <strong>You must tell your doctor if you think that you are (or might become) pregnant </strong></p><p>Your doctor will normally advise you to stop taking Co-Valista before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Co-Valista . Co-Valista is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p>● <strong>Tell your doctor if you are breast-feeding or about to start breast-feeding</strong></p><p>Co-Valista is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p><strong>Driving and using machines</strong></p><p>&nbsp;Before you drive a vehicle, use tools or operate machines or carry out other activities that require concentration, make sure you know how Co-Valista affects you. Like many other medicines used to treat high blood pressure, Co-Valista may occasionally cause dizziness and affect the ability to concentrate.</p><p><strong>Co-Valista contains lactose</strong></p><p>If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p><strong>Co-Valista contains soya oil</strong></p><p>If you are allergic to peanut or soya, do not take this medicinal product.</p><p><strong>Co-Valista 160/12.5 mg contains Sunset yellow FCF (E110) </strong></p><p>This may cause allergic reactions.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. This will help you to get the best results and lower the risk of side effects. Check with your doctor or pharmacist if you are not sure.</p><p>People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with your doctor even if you are feeling well.</p><p>Your doctor will tell you exactly how many tablets of Co-Valista to take. Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.</p><p>● The recommended dose of Co-Valista is one tablet per day.</p><p>● Do not change the dose or stop taking the tablets without consulting your doctor.</p><p>● The medicine should be taken at the same time each day, usually in the morning.</p><p>● You can take Co-Valista with or without food.</p><p>● Swallow the tablet with a glass of water.</p><p><strong>If you take more Co-Valista than you should</strong></p><p>If you experience severe dizziness and/or fainting, lay down and contact your doctor immediately. If you have accidentally taken too many tablets, contact your doctor, pharmacist or hospital.</p><p><strong>If you forget to take Co-Valista</strong></p><p>If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Co-Valista</strong></p><p>Stopping your treatment with Co-Valista may cause your high blood pressure to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>These side effects may occur with certain frequencies, which are defined as follows:</p><p>▪ very common: affects more than 1 user in 10</p><p>▪ common: affects 1 to 10 users in 100</p><p>▪ uncommon: affects 1 to 10 users in 1,000</p><p>▪ rare: affects 1 to 10 users in 10,000</p><p>▪ very rare: affects less than 1 user in 10,000</p><p>▪ not known: frequency cannot be estimated from the available data</p><p><strong>Some side effects can be serious and need immediate medical attention:</strong></p><p>You should see your doctor immediately if you experience symptoms of angioedema, such as:</p><p>● swollen face, tongue or pharynx</p><p>● difficulty in swallowing</p><p>● hives and difficulties in breathing Other side effects include: Uncommon</p><p>● cough</p><p>● low blood pressure</p><p>● light-headedness</p><p>● dehydration (with symptoms of thirst, dry mouth and tongue, infrequent urination, dark colored urine, dry skin)</p><p>● muscle pain</p><p>● tiredness</p><p>● tingling or numbness</p><p>● blurred vision</p><p>● noises (e.g. hissing, buzzing) in ears Very rare</p><p>● dizziness</p><p>● diarrhea</p><p>● joint pain Not known</p><p>● breathing difficulty</p><p>● severely decreased urine output</p><p>● low level of sodium in the blood (sometimes with nausea, tiredness, confusion, malaise, convulsions)</p><p>● low level of potassium in the blood (sometimes with muscle weakness, muscle spasms, abnormal heart rhythm)</p><p>● low level of white cells in the blood (with symptoms such as fever, skin infections, sore throat or mouth ulcers due to infections, weakness)</p><p>● the level of bilirubin increased in blood (which can, in severe cases, trigger yellow skin and eyes)</p><p>● the level of blood urea nitrogen and creatinine increased in blood (which can indicate abnormal kidney function)</p><p>● the level of uric acid in blood increased (which can, in severe cases, trigger gout)</p><p>● syncope (fainting)</p><p>&nbsp;</p><p>Side effects reported with valsartan or hydrochlorothiazide alone, but not observed with Co-Valista :</p><p><u>Valsartan</u></p><p><em>Uncommon</em></p><p>● spinning sensation</p><p>● abdominal pain</p><p><em>Not known </em></p><p>● skin rash with or without itching together with some of the following signs or symptoms: fever, joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms</p><p>● rash, purplish-red spots, fever, itching (symptoms of inflammation of blood vessels)</p><p>● low level of blood platelets (sometimes with unusual bleeding or bruising)</p><p>● high level of potassium in the blood (sometimes with muscle spasms, abnormal heart rhythm)</p><p>● allergic reactions (with symptoms such as rash, itching, hives, difficulty breathing or swallowing, dizziness)</p><p>● swelling of the face and throat</p><p>● elevation of liver function values</p><p>● the level of haemoglobin decreased and the percentage of red cells decreased in the blood (which both can, in severe cases, trigger an anaemia).</p><p>● kidney failure</p><p><u>Hydrochlorothiazide</u></p><p><em>Common</em></p><p>● itchy rash and other types of rash</p><p>● reduced appetite</p><p>● mild nausea and vomiting</p><p>● faintness, fainting on standing up</p><p>● impotence.</p><p><em>Rare</em></p><p>● swelling and blistering of the skin (due to increased sensitivity to sun)</p><p>● constipation, discomfort of the stomach or bowels, liver disorders (yellow skin or eyes)</p><p>● irregular heart beat</p><p>● headache</p><p>● sleep disturbances</p><p>● sad mood (depression)</p><p>● low level of blood platelets (sometimes with bleeding or bruising underneath the skin).</p><p><em>Very rare</em></p><p>● inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever</p><p>● itching or red skin</p><p>● blistering of the lips, eyes or mouth</p><p>● skin peeling</p><p>● fever</p><p>● facial rash associated with joint pain&nbsp;</p><p>● muscle disorder</p><p>● fever (cutaneous lupus erythematosus)</p><p>● severe upper stomach pain; lack or low levels of different blood cells</p><p>● severe allergic reactions</p><p>● difficulty breathing</p><p>● lung infection; breathlessness</p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet</strong>.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>● Keep this medicine out of the sight and reach of children.</p><p>● Do not use this medicine after the expiry date which is stated on the carton, blister and tablet container as EXP. The expiry date refers to the last day of that month.</p><p>● Do not store above 30&deg;C. Store in original pack to protect from moisture and heat.</p><p>● Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are valsartan and hydrochlorothiazide.</p><p>Each film-coated tablet contains 80 mg valsartan and 12.5 mg hydrochlorothiazide.</p><p>Each film-coated tablet contains 160 mg valsartan and 12.5 mg hydrochlorothiazide.</p><p>Each film-coated tablet contains 160 mg valsartan and 25 mg hydrochlorothiazide.</p><p>Each film-coated tablet contains 320 mg valsartan and 12.5 mg hydrochlorothiazide.</p><p>Each film-coated tablet contains 320 mg valsartan and 25 mg hydrochlorothiazide.</p><p>- The other ingredients are:</p><p><em>tablet core:</em></p><p>Microcrystalline Cellulose, Lactose Monohydrate, Croscarmellose Sodium, Povidone K29-K32, Talc, Magnesium Stearate, Colloidal Anhydrous Silica;</p><p><em>film-coat:</em></p><p>[80/12.5 mg tablets] Polyvinyl Alcohol, Talc, Titanium Dioxide (E171), Macrogol 3350, Lecithin (contains soya oil) (E322), Iron Oxide Red (E172), Iron Oxide Yellow (E172), Iron Oxide Black (E172).</p><p>[160/12.5 mg tablets] Polyvinyl Alcohol, Talc , Macrogol 3350, Titanium Dioxide (E171), Iron Oxide Red (E172), Sunset Yellow FCF Aluminium Lake (E110), Lecithin (contains soya oil) (E322).</p><p>[160/25 mg tablets] Polyvinyl Alcohol, Talc , Titanium Dioxide (E171), Macrogol 3350, Iron Oxide Yellow (E172), Lecithin (contains soya oil) (E322), Iron Oxide Red (E172), Iron Oxide Black (E172).</p><p>[320/12.5 mg tablets] Polyvinyl Alcohol, Talc , Titanium Dioxide (E171), Macrogol 3350, Iron Oxide Yellow (E172), Lecithin (contains soya oil) (E322), Iron Oxide Red (E172).</p><p>[320/25 mg tablets] Polyvinyl Alcohol, Talc , Titanium Dioxide (E171), Macrogol 3350, Iron Oxide Yellow (E172), Lecithin (contains soya oil) (E322), Iron Oxide Red (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Co-Valista 80 mg/12.5 mg film-coated tablets: Pink, oval, biconvex film-coated tablets, 11 x 
5.8 mm, marked ‘V’ on one side and ‘H’ on the other. 
Co-Valista 160 mg/12.5 mg film-coated tablets: Red, oval, biconvex film-coated tablets, 15 x 
6 mm, marked ‘V’ on one side and ‘H’ on the other. 
Co-Valista 160 mg/25 mg film-coated tablets: Orange, oval, biconvex film-coated  tablets, 15 
x 6 mm, marked ‘V’ on one side and ‘H’ on the other. 
Co-Valista 320 mg/12.5 mg film-coated tablets: Pink, oval, biconvex film-coated  tablets, 18.9 
x 7.5 mm, marked ‘V’ on one side and ‘H’ on the other. 
Co-Valista 320 mg/25 mg film-coated tablets: Yellow, oval, biconvex film-coated  tablets, 
18.9 x 7.5 mm, marked ‘V’ on one side and ‘H’ on the other.


PVC/PE/PVDC Al Blister and OPA/AL/PVC Blister. 
Blister: 
7, 14, 28, 30, 56, 98 and 280 tablets. 
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by:</p><p>SPIMACO</p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>أقراص كوڤاليستا هى أقراص مغطاة بطبقة رقيقة تحتوى على مادتين فعالتين هما ڤالسارتان و هيدروكلوروثيازيد. كلا المادتان تساعدان على التحكم فى ارتفاع ضغط الدم.</p><p>&middot; ڤالسارتان هى مادة دوائية تنتمى إلى مجموعة من الأدوية التى تسمى مضادات مستقبل أنجيوتنسين-II، والتى تساعد على التحكم فى ارتفاع ضغط الدم. أنجيوتنسين-II هى مادة يتم إنتاجها عن طريق الجسم والتى تسبب تضيق فى الأوعية الدموية، مما يسبب ارتفاع ضغط الدم. ڤالسارتان يعمل على إبطال مفعول مادة أنجيوتنسين-II. مسبباً بذلك ارتخاء فى الأوعية الدموية وانخفاض ضغط الدم.</p><p>&middot; هيدروكلوروثيازيد هى مادة دوائية تنتمى إلى مجموعة من الأدوية تسمى مدرات البول الثيازيدية (وتسمى أيضاً &quot;أقراص الماء&quot;). هيدروكلوروثيازيد يزيد من إنتاج البول، مما يسبب أيضاً انخفاض ضغط الدم.</p><p>كوڤاليستا يستخدم كعلاج للسيطرة على ارتفاع ضغط الدم الذى لا يمكن السيطرة عليه بشكلٍ كافِ باستخدام مادة دوائية واحدة فقط.</p><p>ارتفاع ضغط الدم يزيد من عبء العمل على القلب والشرايين. إذا لم يعالج فإنه من الممكن أن يلحق الضرر بالأوعية الدموية فى المخ والقلب والكلى ومن ثم قد يؤدي إلى فشل القلب أوالسكتة الدماغية أو الفشل الكلوي. ارتفاع ضغط الدم يزيد من خطر الإصابة بالنوبات القلبية. خفض ضغط الدم إلى وضعه الطبيعي يقلل من خطر تطور هذه الاضطرابات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تقم بتناول أقراص كوڤاليستا فى الحالات الآتية:</p><p>&middot; إذا كنت تعانى من فرط التحسس تجاه ڤالسارتان أو هيدروكلوروثيازيد أو مشتقات السلفوناميد (وهى مواد ذات صلة كيميائية بهيدروكلوروثيازيد) أو زيت الصويا أو زيت الفول السودانى أو أى من المكونات الأخرى لهذا الدواء (والمذكورة فى الفقرة 6).</p><p>&middot; إذا كنتِ <strong>فيما بعد الشهر الثالث من الحمل</strong> (فإنه من الأفضل أيضاً تجنب استخدام أقراص كوڤاليستا فى المرحلة المبكرة من الحمل- انظرى فقرة الحمل).</p><p>&middot; إذا كنت تعانى من مرض<strong> حاد</strong> بالكبد.</p><p>&middot; إذا كنت تعانى من مرض<strong> حاد</strong> بالكلى.</p><p>&middot; إذا كنت لا تستطيع التبول.</p><p>&middot; إذا كنت قد خضعت لزرع كلية صناعية.</p><p>&middot; إذا كنت تعانى من انخفاض مستوى البوتاسيوم أو الصوديوم فى الدم عن المعدل الطبيعى أو ارتفاع مستوى الكالسيوم فى الدم عن المعدل الطبيعى بالرغم من العلاج.</p><p>&middot; إذا كنت تعانى من مرض النقرس.</p><p><strong>فى حالة انطباق أى من هذه الحالات المذكورة أعلاه عليك، لا تقم بتناول أقراص كوڤاليستا وتواصل مع طبيبك المعالج.</strong></p><p>ا<strong>لتحذيرات والاحتياطات</strong></p><p>تواصل مع طبيبك المعالج أو الصيدلى قبل البدء فى تناول أقراص كوڤاليستا، خصوصاً فى الحالات الآتية:</p><p>&middot; إذا كنت تتناول أدوية مدخرة للبوتاسيوم أو مكملات البوتاسيوم أو بدائل الملح التى تحتوى على البوتاسيوم أو أى أدوية أخرى تسبب زيادة مستوى البوتاسيوم فى الدم مثل الهيبارين. فحينها قد يحتاج طبيبك المعالج إلى إجراء فحص لمستوى البوتاسيوم فى الدم لديك بشكل منتظم.</p><p>&middot; إذا كان لديك انخفاض فى مستوى البوتاسيوم فى الدم.</p><p>&middot; إذا كنت تعانى من إسهال أو تقيؤ شديد.</p><p>&middot; إذا كنت تتناول جرعات عالية من أقراص الماء (مدرات البول).</p><p>&middot; إذا كنت مصاباً بمرض حاد بالقلب.</p><p>&middot; إذا كنت تعانى من تضيق الشريان الكلوى.</p><p>&middot; إذا كنت قد خضعت مؤخراً لعملية زراعة كلية (حصلت على كلية جديدة).</p><p>&middot; إذا كنت تعاني من ألدوستيرونية. وهو مرض تقوم فيه الغدة الكظرية بإفراز كمية كبيرة من هرمون الألدوستيرون. إذا كانت تنطبق عليك هذه الحالة، فلا ينصح باستخدامك لأقراص كوڤاليستا.</p><p>&middot; إذا كنت مصاباً بمرض بالكبد أو بالكلى.</p><p>&middot; إذا كانت لديك حمى و طفح جلدى وآلام بالمفاصل والتي قد تكون علامات الذئبة الحمراء (SLE وهو مرض يسمى المناعة الذاتية).</p><p>&middot; إذا كنت مصاباً بمرض السكر أو النقرس أو لديك ارتفاع فى مستويات الكوليستيرول أو الدهون فى الدم.</p><p>&middot; إذا كنت قد تعرضت لتفاعلات تحسسية عند استخدام أدوية أخرى لخفض ضغط الدم من هذه المجموعة (مضادات مستقبل أنجيوتنسين-II) أو إذا كانت لديك حساسية أو ربو.</p><p>&middot; قد تسبب زيادة حساسية الجلد تجاه الشمس.</p><p><strong>الأطفال والمراهقين</strong></p><p>لا يوصى باستخدام أقراص كوڤاليستا للأطفال والمراهقين (الأقل فى العمر من 18 سنة).</p><p>يجب عليكِ إخبار طبيبك المعالج إذا كنتِ تعتقدين بأنكِ (أو <u>ربما تصبحين</u>) حامل. حيث أنه لا ينصح باستخدام أقراص كوڤاليستا فى المرحلة المبكرة من الحمل، ويجب عدم تناول أقراص كوڤاليستا إذا كنتِ فيما بعد الشهر الثالث من الحمل، حيث أنه قد يسبب ضرراً جسيماً للجنين إذا ما تم تناوله فى هذه المرحلة من الحمل (انظرى فقرة الحمل).</p><p><strong>تناول كوڤاليستا مع أدوية أخرى</strong></p><p>أخبر طبيبك المعالج إذا كنت تتناول حالياً أو تناولت مؤخراً أى أدوية أخرى.</p><p>حيث أن تأثير العلاج قد يتأثر فى حالة تناول أقراص كوڤاليستا مع بعض الأدوية الأخرى. فقد يكون من الضرورى تغيير الجرعة أو اتخاذ بعض الاحتياطات أو فى بعض الحالات إيقاف استخدام أحد هذه الأدوية. ذلك ينطبق بشكل خاص على الأدوية الآتية:</p><p>&middot; الليثيوم، وهو دواء يستخدم لعلاج بعض الأمراض النفسية.</p><p>&middot; الأدوية التى تؤثر أو قد تتأثر بمستوى البوتاسيوم فى الدم مثل الديجوكسين وهو دواء يستخدم للتحكم فى إيقاع القلب وبعض الأدوية المضادة للذهان.</p><p>&middot; الأدوية التى قد تسبب زيادة مستوى البوتاسيوم فى الدم. والتى تشمل مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم و الأدوية المدخرة للبوتاسيوم والهيبارين.</p><p>&middot; الأدوية التى قد تسبب نقص مستوى البوتاسيوم فى الدم مثل الكورتيزونات وبعض الملينات.</p><p>&middot; مدرات البول (أقراص الماء) أو الأدوية المعالجة للنقرس مثل ألوبيورينول أو المكملات العلاجية التى تحتوى على الكالسيوم وفيتامين د أو الأدوية المعالجة لمرض السكر (سواء كانت عن طريق الفم أو الإنسولينات).</p><p>&middot; أدوية أخرى لخفض ضغط الدم مثل حاصرات بيتا أو ميثيل دوبا أو الأدوية التي تسبب تضيق الأوعية الدموية أو تساعد على تنشيط القلب مثل النورأدرينالين أو الأدرينالين.</p><p>&middot; الأدوية التى تسبب زيادة مستوي السكر في الدم مثل ديازوكسيد.</p><p>&middot; الأدوية التى تعالج السرطان مثل ميثوتريكسات أو سيكلوفوسفاميد.</p><p>&middot; مسكنات الألم.</p><p>&middot; أدوية التهاب المفاصل.</p><p>&middot; الأدوية الباسطة للعضلات مثل توبوكورارين.</p><p>&middot; الأدوية المضادة للكولين مثل الأتروبين أو بيبيريدين.</p><p>&middot; الأمانتادين (وهو دواء يستخدم للوقاية من الانفلونزا).</p><p>&middot; كولستيرامين وكوليستيبول (وهى أدوية تستخدم لعلاج ارتفاع مستوي الدهون في الدم).</p><p>&middot; سيكلوسبورين وهو دواء يستخدم فى زراعة الأعضاء لتجنب رفض العضو المزروع.</p><p>&middot; بعض المضادات الحيوية (مثل تتراسكلين) ومواد التخدير والمهدئات.</p><p>&middot; كاربامازيبين وهو دواء يستخدم لعلاج حالات الصرع.</p><p><strong>تناول أقراص كوڤاليستا مع الطعام والشراب</strong></p><p>يمكن تناول أقراص كوڤاليستا مع الطعام أو بدونه. تجنب تناول الكحول لحين التحدث إلى طبيبك المعالج. حيث أن الكحول قد يزيد من خفض ضغط الدم و / أو يزيد من خطر الإصابة بالدوخة أو الشعور بالإغماء.</p><p><strong>الحمل والرضاعة</strong></p><p>إذا كنتِ حامل أو إذا كنتِ تعتقدين بأنكِ ربما تكونى حامل أو تخططين للإنجاب أو تقومين بإرضاع طفلك طبيعياً، اسألى طبيبك المعالج أو الصيدلى للمشورة قبل البدء فى تناول هذا الدواء.</p><p>&middot;<strong> يجب عليكِ إخبار طبيبك المعالج إذا كنتِ تعتقدين بأنكِ (أو ربما تصبحين) حامل</strong>. فمن الطبيعى أن ينصحك طبيبك المعالج بالتوقف عن تناول أقراص كوڤاليستا قبل أن تصبحى حامل أو بمجرد معرفتك بالحمل، وسوف يقوم بوصف دواء آخر لكِ بدلاً من كوڤاليستا، حيث أنه لا يوصى باستخدام أقراص كوڤاليستا فى المرحلة المبكرة من الحمل،</p><p>ويجب عدم تناوله فيما بعد الشهر الثالث من الحمل، حيث أنه قد يسبب ضرراً جسيماً للجنين إذا ما تم تناوله فى مرحلة ما بعد الشهر الثالث من الحمل.</p><p><strong>&middot; يجب عليكِ إخبار طبيبك المعالج إذا كنتِ تقومين أو ستبدئين فى إرضاع طفلك طبيعياً.</strong> حيث أنه لا يوصى باستخدام أقراص كوڤاليستا للأمهات أثناء الرضاعة الطبيعية، وقد يصف لكِ طبيبك المعالج دواء آخر إذا كنتِ ترغبين بالاستمرار فى الإرضاع طبيعياً، خصوصاً إذا كان طفلك حديث الولادة أو مولود قبل أوانه.</p><p>ا<strong>لقيادة واستخدام الآلات</strong></p><p>قبل البدء فى قيادة السيارة أو استخدام الأدوات أو تشغيل الماكينات أو القيام بأى أعمال أخرى تستلزم التركيز، يجب أولاً أن تعرف مدى تأثير أقراص كوڤاليستا عليك. مثل بقية الأدوية التى تستخدم لخفض ضغط الدم، كوڤاليستا قد يسبب فى بعض الأحيان دوخة ويؤثر على القدرة على التركيز.</p><p><strong>كوڤاليستا يحتوى على سكر اللاكتوز</strong></p><p>إذا أخبرك طبيبك المعالج بعدم استطاعتك لتحمل بعض أنواع السكر، تواصل مع طبيبك المعالج قبل البدء فى تناول هذا الدواء.</p><p><strong>كوڤاليستا يحتوى على زيت الصويا</strong></p><p>إذا كنت تعانى من فرط التحسس تجاه الصويا أو الفول السودانى، لا تقم بتناول هذا الدواء.</p><p><strong>كوڤاليستا 160 ملجم12.5/ ملجم يحتوى على مادة (110E (FCF الصفراء</strong> والتى قد تسبب تفاعلات تحسسية</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائماً بتناول أقراص كوڤاليستا بالضبط كما أخبرك طبيبك المعالج. سوف يساعد ذلك فى الحصول على أفضل النتائج وتقليل خطر الإصابة بالأعراض الجانبية. إذا كنت غير متأكد، يجب أن تتأكد من خلال التواصل مع طبيبك المعالج أو الصيدلى.</p><p>فى أغلب الأحيان الناس المصابة بارتفاع ضغط الدم لا يقومون بملاحظة أى علامات لهذه المشكلة. فقد يشعر الكثير منهم بأنه طبيعى تماماً. مما يجعل الأمر أكثر أهمية بالنسبة لك للحفاظ على مواعيدك مع الطبيب المعالج حتى لو كنت تشعر بأنك على ما يرام.</p><p>سوف يخبرك الطبيب المعالج كم عدد الأقراص بالضبط المفترض عليك تناولها. اعتماداً على مدى استجابتك للعلاج، وقد يلجأ طبيبك المعالج إلى زيادة أو إنقاص الجرعة.</p><p>&middot; الجرعة التى يوصى بها من أقراص كوڤاليستا هى قرص واحد يومياً.</p><p>&middot; لا تقم بتغيير الجرعة أو التوقف عن تناول العلاج بدون استشارة طبيبك المعالج.</p><p>&middot; من المفروض تناول العلاج فى نفس الوقت يومياً، والذى يكون عادةً فى الصباح.</p><p>&middot; يمكن تناول أقراص كوڤاليستا مع الطعام أو بدونه.</p><p>&middot; قم بابتلاع القرص مع كوب من الماء.</p><p><strong>فى حالة تناولك لأقراص كوڤاليستا أكثر مما ينبغى</strong></p><p>إذا تعرضت لدوار شديد و/ أو إغماء، استلقِ أفقياً واتصل بطبيبك المعالج فوراً. إذا تناولت خطئاً العديد من الأقراص، اتصل بالطبيب أو الصيدلى أو المستشفى فى الحال.</p><p><strong>فى حالة نسيان تناول أقراص كوڤاليستا</strong></p><p>فى حالة نسيان تناول الجرعة، قم بتناولها بمجرد أن تتذكر. إلا إذا كان هذا الوقت تقريباً هو وقت الجرعة التالية، فى هذه الحالة تخطى الجرعة المفقودة.</p><p>لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المفقودة.</p><p><strong>فى حالة التوقف عن تناول أقراص كوڤاليستا</strong></p><p>توقفك عن تناول أقراص كوڤاليستا قد يؤدى إلى تدهور حالتك. لا تتوقف عن تناول العلاج الخاص بك ما لم يخبرك طبيبك المعالج بذلك.</p><p><strong>إذا كانت لديك أى أسئلة إضافية بشأن استخدام هذا الدواء، إسأل طبيبك المعالج أو الصيدلى.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، هذا الدواء قد يسبب آثار جانبية، وإن لم تكن تحدث لكل من يتناول هذا الدواء.</p><p>هذه الأعراض الجانبية قد تحدث بمعدلات معينة يمكن تعريفها كالآتى:</p><p>&middot; شائعة جداً: والتى تصيب أكثر من 1 لكل 10 مستخدمين لهذا الدواء.</p><p>&middot; شائعة: والتى تصيب من 1 إلى 10 لكل 100 مستخدم لهذا الدواء.</p><p>&middot; غير شائعة: والتى تصيب من 1 إلى 10 لكل 1000 مستخدم لهذا الدواء.</p><p>&middot; نادرة: والتى تصيب من 1 إلى 10 لكل 10,000 مستخدم لهذا الدواء.</p><p>&middot; نادرة جداً: والتى تصيب أقل من 1 لكل 10,000 مستخدم لهذا الدواء.</p><p>&middot; غير معلومة: والتى لا يمكن تقدير معدل تكرار حدوثها من خلال البيانات المتاحة.</p><p><strong>بعض الأعراض التى تتطلب عناية طبية عاجلة:</strong></p><p>يجب عليك زيارة طبيبك المعالج فوراً فى حالة تعرضك للإصابة بأعراض الوذمة الوعائية، مثل:</p><p>&middot; تورم الوجه أو اللسان أو البلعوم.</p><p>&middot; صعوبة فى البلع.</p><p>&middot; الشرى وصعوبة فى التنفس.</p><p>&nbsp;</p><p><strong>أعراض جانبية أخرى وتشمل:</strong></p><p>غير شائعة:</p><p>&middot; سعال</p><p>&middot; انخفاض ضغط الدم</p><p>&middot; دوار</p><p>&middot; جفاف (مصحوباً بأعراض العطش، جفاف الفم واللسان، ندرة التبول، تغير لون البول إلى اللون الداكن، جفاف الجلد)</p><p>&middot; ألم بالعضلات</p><p>&middot; إرهاق</p><p>&middot; وخز أو تنميل</p><p>&middot; عدم وضوح الرؤية</p><p>&middot; ضوضاء (مثل هسهسة أو طنين) في الأذنين</p><p>نادرة جداً:</p><p>&middot; دوخة</p><p>&middot; إسهال</p><p>&middot; ألم بالفاصل</p><p>غير معلومة:</p><p>&middot; صعوبة في التنفس</p><p>&middot; انخفاض شديد فى كمية البول</p><p>&middot; انخفاض مستوى الصوديوم في الدم (أحيانا يصاحبه غثيان وتعب وارتباك وشعور بالضيق وتشنجات)</p><p>&middot; انخفاض مستوى البوتاسيوم في الدم (أحيانا يصاحبه ضعف العضلات وتشنجات العضلات وعدم انتظام إيقاع ضربات القلب)</p><p>&middot; انخفاض مستوى الخلايا البيضاء في الدم (مع أعراض مثل الحمى والتهابات الجلد والتهاب الحلق أو قرح الفم الناجمة عن الالتهابات وضعف)</p><p>&middot; زيادة مستوى البيليروبين في الدم (والتي قد تؤدي إلى اصفرار العين والجلد في الحالات الشديدة)</p><p>&middot; زيادة مستوى نيتروجين يوريا في الدم والكرياتينين في الدم (والتي يمكن أن تشير إلى خلل فى وظائف الكلى)</p><p>&middot; زيادة مستوى حمض اليوريك في الدم (والتي قد تؤدى إلى النقرس في الحالات الشديدة)</p><p>&middot; فقدان الوعي (إغماء)</p><p><strong>أعراض جانبية تم تسجيلها مع ڤالسارتان أو هيدروكلوروثيازيد كل على حدة، ولكنها لا تظهر مع كوڤاليستا:</strong></p><p><u><strong>ڤالسارتان</strong></u></p><p>غير شائعة:</p><p>&middot; إحساس بالدوار</p><p>&middot; ألم بالبطن</p><p>غير معلومة:</p><p>&middot; طفح جلدي مع أو بدون حكة جنباً إلى جنب مع بعض العلامات أو الأعراض التالية: حمى و آلام المفاصل وآلام في العضلات و تضخم الغدد الليمفاوية و / أو أعراض شبيهة بالأنفلونزا)</p><p>&middot; بقع ذات لون أحمر أرجواني وحمى وحكة (علامات التهاب الأوعية الدموية).</p><p>&middot; نقص عدد الصفائح الدموية (مصحوباً فى بعض الأحيان بكدمات أو نزيف غير معتاد)</p><p>&middot; ارتفاع مستوى البوتاسيوم بالدم (والذى يصاحبه أحياناً تقلص بالعضلات وعدم انتظام إيقاع القلب)</p><p>&middot; تفاعلات تحسسية (مصحوبة بأعراض مثل طفح جلدى، حكة، شرى، صعوبة فى التنفس أو البلع، دوخة)</p><p>&middot; تورم الوجه والحلق</p><p>&middot; ارتفاع قيم وظائف الكبد</p><p>&middot; انخفاض مستوى الهيموجلوبين وانخفاض نسبة خلايا الدم الحمراء في الدم (والذي قد يؤدي إلى فقر الدم في الحالات الشديدة)</p><p>&middot; فشل كلوى</p><p><u><strong>هيدروكلوروثيازيد</strong></u></p><p>شائعة:</p><p>&middot; طفح جلدى مصحوباً بحكة وأنواع أخرى من الطفح الجلدى</p><p>&middot; خفض الشهية</p><p>&middot; غثيان خفيف وتقيؤ</p><p>&middot; ضعف أو إغماء عند الوقوف</p><p>&middot; عجز جنسي</p><p>نادرة:</p><p>&middot; تورم وظهور تقرحات في الجلد (بسبب زيادة الحساسية للشمس)</p><p>&middot; إمساك وعدم راحة في المعدة أو الأمعاء واضطرابات الكبد (اصفرار الجلد واصفرار بياض العينين)</p><p>&middot; عدم انتظام ضربات القلب</p><p>&middot; صداع</p><p>&middot; اضطرابات فى النوم</p><p>&middot; انخفاض الحالة المزاجية (اكتئاب)</p><p>&middot; انخفاض عدد الصفائح الدموية</p><p>نادرة جداً:</p><p>&middot; التهاب الأوعية الدموية مصحوباً بأعراض مثل الطفح الجلدى وبقع ذات لون أحمر أرجوانى وحمى</p><p>&middot; حكة أو احمرار فى الجلد</p><p>&middot; ظهور تقرحات في الشفتين أوالعينين أو الفم</p><p>&middot; تقشير الجلد</p><p>&middot; حمى</p><p>&middot; طفح في الوجه مقترناً بآلام المفاصل</p><p>&middot; اضطراب العضلات</p><p>&middot; حمى (الذئبة الحمامية الجلدية)</p><p>&middot; ألم شديد فى الجزء العلوى من المعدة، نقص فى مستوى خلايا الدم المختلفة</p><p>&middot; تفاعلات تحسسية شديدة</p><p>&middot; صعوبة فى التنفس</p><p>&middot; عدوى بالرئة مع ضيق التنفس</p><p><strong>إذا تعرضت للإصابة بأى أعراض جانبية تواصل مع طبيبك المعالج أو الصيدلى. ويشمل ذلك الأعراض الجانبية التى لم يتم ذكرها فى هذه النشرة.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot; يحفظ هذا الدواء بعيداً عن متناول ونظر الأطفال.</p><p>&middot; لا تستخدم أقراص كوڤاليستا بعد انتهاء تاريخ الصلاحية المدون على العبوة والشريط بعد EXP، علماً بأن تاريخ الصلاحية يشير إلى آخر يوم من الشهر المدون على العلبة.</p><p>&middot; لا تحفظ فى درجة حرارة أعلى من 30 درجة مئوية. يحفظ في العبوة الأصلية للحماية من الرطوبة و الحرارة.</p><p>&middot; لا يجب التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>المادتان الفعالتان هما : ڤالسارتان و هيدروكلوروثيازيد .</li></ul><p>كل قرص مغطى بطبقة رقيقة يحتوى على 80 ملجم من ڤالسارتان و 12.5 ملجم من هيدروكلوروثيازيد.</p><p>كل قرص مغطى بطبقة رقيقة يحتوى على 160 ملجم من ڤالسارتان و 12.5 ملجم من هيدروكلوروثيازيد .</p><p>كل قرص مغطى بطبقة رقيقة يحتوى على 160 ملجم من ڤالسارتان و 25 ملجم من هيدروكلوروثيازيد.</p><p>كل قرص مغطى بطبقة رقيقة يحتوي على 320 ملجم من ڤالسارتان و 12.5 ملجم من هيدروكلوروثيازيد .</p><p>كل قرص مغطى بطبقة رقيقة يحتوي على 320 ملجم من ڤالسارتان و 25 ملجم من هيدروكلوروثيازيد.</p><ul><li dir="rtl">&nbsp;مكونات أخرى وهى:</li></ul><p>لب القرص: ميكروكريستالين سيليولوز, لاكتوز مونوهيدرات, كروسكارميللوز صوديوم, بوفيدون 32K29-K, تالك, ستيارات المغنسيوم, سيليكا غروية لامائية.&nbsp;</p><p>طبقة التغليف الرقيقة :</p><ul><li>كوڤاليستا 80 ملجم/ 12.5ملجم أقراص مغطاة بطبقة رقيقة: بولي فينيل الكحول, تالك, ثانى أكسيد التيتانيوم (171E) ,&nbsp; ماكروجول ,3350 ليسيثين (يحتوى على زيت الصويا)(322E) , أكسيد الحديد الاصفر (172E ), ( أكسيد الحديد الاحمر (172E) , أكسيد الحديد الاسود (172E)</li><li dir="rtl">&nbsp;كوڤاليستا 160 ملجم/ 12.5ملجم أقراص مغطاة بطبقة رقيقة: بولي فينيل الكحول, تالك, ماكروجول ,3350 ثانى أكسيد التيتانيوم (171E) , ( أكسيد الحديد الاحمر (172E , ( FCF ألومنيوم أصفر لامع (110E), ليسيثين (يحتوى على زيت الصويا)(322E) .</li><li dir="rtl">&nbsp;كوڤاليستا 160 ملجم/ 25 ملجم أقراص مغطاة بطبقة رقيقة: : بولي فينيل الكحول, تالك, ثانى أكسيد التيتانيوم (171E)&nbsp;, ماكروجول ,3350 أكسيد الحديد الاصفر (172E) ,&nbsp; ليسيثين (يحتوى على زيت الصويا)(322E) ,&nbsp; أكسيد الحديد الاحمر (172E) ,&nbsp; أكسيد الحديد الاسود (172E) .</li><li dir="rtl">كوڤاليستا 320ملجم/12.5 ملجم أقراص مغطاة بطبقة رقيقة : بولي فينيل الكحول، تالك، ثاني أكسيد التيتانيوم (171E ),ماكروجول 3350 ، ليسيثين( يحتوي على زيت الصويا ( 322E ) , أكسيد الحديد الاصفر (171E) ,أكسيد الحديد الاحمر (172E) .</li><li dir="rtl">&nbsp;كوڤاليستا 320ملجم/ 25 ملجم أقراص مغطاة بطبقة رقيقة : بولي فينيل الكحول، تالك، ثاني أكسيد التيتانيوم (171E ), ماكروجول 3350 ، ليسيثين يحتوي على زيت الصويا ( 322E) , ( أكسيد الحديد الاصفر (171E) , أكسيد الحديد الاحمر (172E)</li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كوڤاليستا 80 ملجم/ 12.5ملجم أقراص مغطاة بطبقة رقيقة: أقراص وردية اللون, بيضاوية الشكل, ثنائية التحدب مغطاة بطبقة رقيقة مقاس 11x 5.8 ملم, عليھا علامة &quot;V &quot;من جانب و علامة &ldquo;H &quot;من الجانب الاخر .</p><p>كوڤاليستا 160 ملجم/ 12.5ملجم أقراص مغطاة بطبقة رقيقة: أقراص حمراء اللون, بيضاوية الشكل, ثنائية التحدب مغطاة بطبقة رقيقة مقاس 15x 6 ملم, عليھا علامة &quot;V &quot;من جانب و علامة &quot;H&quot;من الجانب الاخر .</p><p>كوڤاليستا 160 ملجم/25ملجم أقراص مغطاة بطبقة رقيقة: أقراص برتقالية اللون, بيضاوية الشكل, ثنائية التحدب مغطاة بطبقة رقيقة مقاس 15x 6 ملم, عليھا علامة &quot;V &quot;من جانب و علامة &quot;H&quot;من الجانب الاخر .</p><p>كوڤاليستا 320ملجم/12.5 ملجم أقراص مغطاة بطبقة رقيقة أقراص مغطاة بطبقة رقيقة : أقراص وردية اللون، بيضاوية الشكل، ثنائية التحدب مغطاة بطبقة رقيقة مقاس 18.9 X 7.5 ملم عليھا علامة &raquo;V &raquo;من جانب و علامة &raquo;H &raquo;من الجانب الاخر .</p><p>كوڤاليستا 320ملجم/ 25 ملجم أقراص مغطاة بطبقة رقيقة أقراص مغطاة بطبقة رقيقة :أقراص وردية اللون، بيضاوية الشكل، ثنائية التحدب مغطاة بطبقة رقيقة مقاس 18.9 X 7.5 ملم عليھا علامة &raquo;V &raquo;من جانب و علامة &raquo;H &raquo;من الجانب الاخر .</p><p>محتويات العبوة :</p><p>شرائط الومنيوم OPA/AL/PVC و PVC/PE/PVDC</p><p>كل عبوة تحتوى على 7 أو 14 أو 28 أو 30 أو 56 أو 98 أو 280 قرص .</p><p>قد لا يتم تسويق جميع أحجام العبوات</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إنتاج:</p><p>الدوائية</p><p>مصنع الأدوية بالقصيم</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية.</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Co- Valista 80 mg/12.5 mg film-coated tablets 
Co- Valista 160 mg/12.5 mg film-coated tablets 
Co- Valista 160 mg/25 mg film-coated tablets 
Co-Valista 320mg/12.5mg film-coated tablets 
Co-Valista 320mg/25mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 80 mg of valsartan and 12.5 mg of hydrochlorothiazide. 
Each tablet contains 160 mg of valsartan and 12.5 mg of hydrochlorothiazide. 
Each tablet contains 160 mg of valsartan and 25 mg of hydrochlorothiazide. 
Each tablet contains 320 mg of valsartan and 12.5 mg of hydrochlorothiazide. 
Each tablet contains 320 mg of valsartan and 25 mg of hydrochlorothiazide. 

Excipients with known effect: 
Each Co- Valista 80 mg/12.5 mg film-coated tablet contains 29.72 mg lactose monohydrate and 
0.25 mg lecithin (contains soya oil). 
Each Co- Valista 160 mg/12.5 mg film-coated tablet contains 71.94 mg lactose monohydrate, 
0.50 mg lecithin (contains soya oil) and 0.56 mg Sunset yellow FCF (E110). 
Each Co- Valista 160 mg/25 mg film-coated tablet contains 59.44 mg lactose monohydrate and 
0.50 mg lecithin (contains soya oil). 
Each Co- Valista 320 mg/12.5 mg film-coated tablet contains 156.38 mg lactose monohydrate 
and 1.01 mg lecithin (contains soya oil). 
Each Co- Valista 320 mg/25 mg film-coated tablet contains 143.88 mg lactose monohydrate and 
1.01 mg lecithin (contains soya oil). 
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet. 
Co- Valista 80 mg/12.5 mg: Pink, oval, biconvex film-coated tablets, 11 x 5.8 mm, marked ‘V’ 
on one side and ‘H’ on the other. 
Co- Valista 160 mg/12.5 mg: Red, oval, biconvex film-coated tablets, 15 x 6 mm, marked ‘V’ on 
one side and ‘H’ on the other. 
Co- Valista 160 mg/25 mg: Orange, oval, biconvex film-coated tabelts, 15 x 6 mm, marked ‘V’ 
on one side and ‘H’ on the other. 
Co-Valista 320 mg/12.5 mg film-coated tablets: Pink, Oval, biconvex, film-coated tablets, 
18.9mm x 7.5mm, marked ‘V’ on one side and ‘H’ on the other. 
Co-Valista 320 mg/25mg film-coated tablets: Yellow, Oval, biconvex, film-coated tablets, 18.9mm x 
7.5mm, marked ‘V’ on one side and ‘H’ on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension in adults. Co- Valista fixed-dose combination is indicated in patients whose blood pressure is not adequately controlled on valsartan or hydrochlorothiazide monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose of Co- Valista X mg/Y mg is one film-coated tablet once daily. Dose titration with the individual components is recommended. In each case, up- titration of individual components to the next dose should be followed in order to reduce the risk of hypotension and other adverse events. When clinically appropriate direct change from monotherapy to the fixed combination may be considered in patients whose blood pressure is not adequately controlled on valsartan or hydrochlorothiazide monotherapy, provided the recommended dose titration sequence for the individual components is followed. The clinical response to Co- Valista should be evaluated after initiating therapy and if blood pressure remains uncontrolled, the dose may be increased by increasing either one of the components to a maximum dose of Co- Valista 320 mg/25 mg. The antihypertensive effect is substantially present within 2 weeks. In most patients, maximal effects are observed within 4 weeks. However, in some patients, 4- 8 weeks treatment may be required. .This should be taken into account during dose-titration.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Co- Valista can be taken with or without food and should be administered with water.</p><p><u>Special populations </u></p><p><em>Renal impairment</em></p><p>No dose adjustment is required for patients with mild to moderate renal impairment (creatinine clearance  30 ml/min). Due to the hydrochlorothiazide component, Co- Valista is contraindicated in patients with severe renal impairment (see sections 4.3, 4.4 and 5.2).</p><p><em>Hepatic impairment</em></p><p>In patients with mild to moderate hepatic impairment without cholestasis the dose of valsartan should not exceed 80 mg (see section 4.4). Co- Valista is contraindicated in patients with severe hepatic impairment (see sections 4.3, 4.4 and 5.2).</p><p><em>Elderly</em></p><p>No dose adjustment is required in elderly patients.</p><p><em>Paediatric population </em></p><p>Co- Valista is not recommended for use in children below the age of 18 years due to a lack of data on safety and efficacy.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to valsartan, hydrochlorothiazide, other sulfonamide-derived medicinal 
products, soya oil, peanut oil or to any of the excipients listed in section 6.1. 
- Second and third trimester of pregnancy (section 4.4 and 4.6). 
- Severe hepatic impairment, biliary cirrhosis and cholestasis. 
- Severe renal impairment (creatinine clearance <30 ml/min), anuria. 
- Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic 
hyperuricaemia. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Serum electrolyte changes </u></p><p><em>Valsartan</em></p><p>Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p><em>Hydrochlorothiazide</em></p><p>Hypokalaemia has been reported under treatment with thiazide diuretics, including hydrochlorothiazide. Frequent monitoring of serum potassium is recommended. Treatment with thiazide diuretics, including hydrochlorothiazide, has been associated with hyponatraemia and hypochloraemic alkalosis. Thiazides, including hydrochlorothiazide, increase the urinary excretion of magnesium, which may result in hypomagnesaemia. Calcium excretion is decreased by thiazide diuretics. This may result in hypercalcaemia. As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.</p><p>&nbsp;</p><p><u><em>Sodium and/or volume-depleted patients </em></u></p><p>Patients receiving thiazide diuretics, including hydrochlorothiazide, should be observed for clinical signs of fluid or electrolyte imbalance. In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with Co- Valista. Sodium and/or volume depletion should be corrected before starting treatment with Co- Valista</p><p>&nbsp;</p><p><u><em>Patients with severe chronic heart failure or other conditions with stimulation of the reninangiotensin-aldosterone-system </em></u></p><p>In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia, and in rare cases with acute renal failure. The use of Co- Valista in patients with severe chronic heart failure has not been established. Hence it cannot be excluded that because of the inhibition of the renin-angiotensin-aldosterone system the application of Co- Valista as well may be associated with impairment of the renal function. Co- Valista should not be used in these patients.</p><p>&nbsp;</p><p><u>Renal artery stenosis </u></p><p>Co- Valista should not be used to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, since blood urea and serum creatinine may increase in such patients.</p><p><u>Primary hyperaldosteronism </u></p><p>Patients with primary hyperaldosteronism should not be treated with Co- Valista as their reninangiotensin system is not activated.</p><p>&nbsp;</p><p><u><em>Aortic and mitral valve stenosis, hypertrophic obstructive cardiomyopathy</em></u></p><p>As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM)</p><p>&nbsp;</p><p><u>Renal impairment </u></p><p>No dosage adjustment is required for patients with renal impairment with a creatinine clearance 30 ml/min (see section 4.2). Periodic monitoring of serum potassium, creatinine and uric acid levels is recommended when Co- Valista is used in patients with renal impairment. Kidney transplantation There is currently no experience on the safe use of valsartan/hydrochlorothiazide in patients who have recently undergone kidney transplantation.</p><p><u><em>Hepatic impairment</em></u></p><p>In patients with mild to moderate hepatic impairment without cholestasis, Co- Valista should be used with caution (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u><em>Systemic lupus erythematosus</em> </u></p><p>Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.</p><p>&nbsp;</p><p><em><u>Other metabolic disturbances </u></em></p><p>Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required. Thiazides may reduce urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia may be evidence of underlying hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p>&nbsp;</p><p><u>Photosensitivity</u></p><p>Cases of photosensitivity reactions have been reported with thiazides diuretics (see section 4.8). If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p><u>Pregnancy</u></p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><u>General</u></p><p>Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.</p><p><u>Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorbtion</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><u>Lecithin</u></p><p>If a patient is hypersensitive to peanut or soya, this medicine should not be used. Co- Valista 160 mg/12.5 mg film-coated tablets also contains Sunset yellow FCF (E110) which can cause hypersensitivity reactions.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interactions related to both valsartan and hydrochlorothiazide</u></p><p><u>Concomitant use not recommended </u></p><p><em>Lithium</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors and thiazide, including hydrochlorothiazide. Due to the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><u>Concomitant use requiring caution Other antihypertensive agents</u></p><p>Co- Valista may increase the effects of other agents with antihypertensive properties (e.g ACEI, beta blockers, calcium channel blockers).</p><p><em>Pressor amines (e.g. noradrenaline, adrenaline)</em></p><p>Possible decreased response to pressor amines but not sufficient to preclude their use.</p><p><em>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid &gt;3 g/day), and non-selective NSAIDs </em></p><p>NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of CoValista and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p><p>&nbsp;</p><p><u>Interactions related to valsartan</u></p><p><u>Concomitant use not recommended</u></p><p>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised.</p><p>No interaction</p><p>In drug interaction studies with valsartan, no interactions of clinical significance have been found with valsartan or any of the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide. Digoxin and indomethacin could interact with the hydrochlorothiazide component of Co- Valista (see interactions related to hydrochlorothiazide).</p><p><u>Interactions related to hydrochlorothiazide</u></p><p><u>Concomitant use requiring caution </u></p><p>Medicinal products associated with potassium loss and hypokalaemia (e.g. kaliuretic diuretics, corticosteroids, laxatives, ACTH, amphotericin, carbenoxolone, penicillin G, salicylic acid and derivatives) If these medicinal products are to be prescribed with the hydrochlorothiazide-valsartan combination, monitoring of potassium plasma levels is advised. These medicinal products may potentiate the effect of hydrochlorothiazide on serum potassium (see section 4.4). Medicinal products that could induce torsades de pointes</p><p>● Class Ia antiarrhythmics (e.g. quinidine, hydroquinidine, disopyramide)</p><p>● Class III antiarrhythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide)</p><p>● Some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol)</p><p>● Others (e.g. bepridil, cisapride, diphemanil, erythromycin i.v., halofantrin, ketanserin, mizolastin, pentamidine, sparfloxacine, terfenadine, vincamine i.v.) Due to the risk of hypokalemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes.</p><p>&nbsp;</p><p><em>Digitalis glycosides </em></p><p>Thiazide-induced hypokalaemia or hypomagnesaemia may occur as unwanted effects favouring the onset of digitalis-induced cardiac arrhythmias.</p><p><em>Calcium salts and vitamin D</em></p><p>Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium.</p><p>Antidiabetic agents (oral agents and insulin) The treatment with a thiazide may influence the glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary. Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p><em>Beta blockers and diazoxide </em></p><p>Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</p><p><em>Medicinal products used in the treatment of gout</em> (probenecid, sulfinpyrazone and allopurinol) Dose adjustment of uricosuric medications may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dosage of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.</p><p><em>Anticholinergic agents (e.g. atropine, biperiden)</em></p><p>The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents, apparently due to a decrease in gastrointestinal motility and the stomach emptying rate.</p><p><em>Amantadine </em></p><p>Thiazides, including hydrochlorothiazide, may increase the risk of adverse effects caused by amantadine Cholestyramine and cholestipol resins Absorption of thiazide diuretics, including hydrochlorothiazide, is impaired in the presence of anionic exchange resins.</p><p><em>Cytotoxic agents (e.g. cyclophosamide, methotrexate)</em></p><p>Thiazides, including hydrochlorothiazide, may reduce renal excretion of cytotoxic agents and potentiate their myelosuppressive effects.</p><p><em>Non-depolarising skeletal muscle relaxants (e.g. tubocurarine) </em></p><p>Thiazides, including hydrochlorothiazide, potentiate the action of curare derivatives.</p><p><em>Ciclosporin</em></p><p>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.</p><p><em>Alcohol, anaesthetics and sedatives </em></p><p>Potentiation of orthostatic hypotension may occur.</p><p><em>Methyldopa</em></p><p>There have been isolated reports of haemolytic anaemia in patients receiving concomitant treatment with methyldopa and hydrochlorothiazide.</p><p><em>Carbamazepine</em></p><p>Patients receiving hydrochlorothiazide concomitantly with carbamazepine may develop hyponatremia. Such patients should therefore be advised about the possibility of hyponatraemic reactions, and should be monitored accordingly.</p><p><em>Iodine contrast media</em></p><p>In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of the iodine product. Patients should be rehydrated before the administration.</p><p><em>Aliskiren</em></p><p>Do not co-administer aliskiren with Co-Valista patients with diabetes. avoid use of aliskren with Co-Valista in patients with renal impairment (GFR &lt;60 ml/ min).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p><em>Pregnancy category D </em></p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started. AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3). Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also section 4.3 and 4.4).</p><p>Hydrochlorothiazide</p><p>There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p><u>Breastfeeding</u></p><p>No information is available regarding the use of valsartan during breastfeeding. Hydrochlorothiazide is excreted in human milk. Therefore the use of Co- Valista during breast feeding is not recommended. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect of Co- Valista, on the ability to drive and use machines have been performed. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions reported in clinical trials and laboratory findings occurring more frequently with valsartan plus hydrochlorothiazide versus placebo and individual postmarketing reports are presented below according to system organ class. Adverse reactions known to occur with each component given individually but which have not been seen in clinical trials may occur during treatment with valsartan/hydrochlorothiazide.</p><p>Adverse drug reactions are ranked by frequency, the most frequent first, using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p>&nbsp;</p><p><u>Table 1. Frequency of adverse reactions with valsartan/hydrochlorothiazide</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dehydration</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Syncope</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vision blurred</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Non cardiogenic pulmonary oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Impaired renal function</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Serum uric acid increased, Serum bilirubin and Serum creatinine increased, Hypokalaemia, Hyponatraemia, Elevation of Blood Urea Nitrogen, Neutropenia</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Additional information on the individual components </u></p><p>Adverse reactions previously reported with one of the individual components may be potential undesirable effects with Co- Valista as well, even if not observed in clinical trials or during postmarketing period.</p><p>&nbsp;</p><p><u>Table 2. Frequency of adverse reactions with valsartan</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Decrease in haemoglobin, decrease in haematocrit, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Other hypersensitivity/allergic reactions including serum sickness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase of serum potassium, hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Elevation of liver function values</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Angioedema, rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>Table 3. Frequency of adverse reactions with hydrocholothiazide</u></p><p>Hydrochlorothiazide has been extensively prescribed for many years, frequently in higher doses than those administered with Co- Valista. The following adverse reactions have been reported in patients treated with monotherapy of thiazide diuretics, including hydrochlorothiazide:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Thrombocytopenia sometimes with purpura</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Agranulocytosis, leucopenia, haemolytic anaemia, bone marrow depression</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hypersenstivity reactions</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Depression, sleep disturbances</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Cardiac arrhythmias</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Postural hypotension</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Respiratory distress including pneumonitis and pulmonary oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Loss of appetite, mild nausea and vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Constipation, gastrointestinal discomfort</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Intrahepatic cholestasis or jaundice</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Urticaria and other forms of rash</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Photosensitisation</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Necrotising vasculitis and toxic epidermal necrolysis, cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Impotence</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" align="center" style="width:500px"><tbody><tr><td><p style="text-align:center"><strong>To report any side effect(s):</strong></p><p style="text-align:center"> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="text-align:center">o Fax: +966-11-205-7662</p><p style="text-align:center">o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p style="text-align:center">o Toll free phone: 8002490000</p><p style="text-align:center">o E-mail: npc.drug@sfda.gov.sa</p><p style="text-align:center">o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Overdose with valsartan may result in marked hypotension, which could lead to depressed level of consciousness, circulatory collapse and/or shock. In addition, the following signs and symptoms may occur due to an overdose of the hydrochlorothiazide component: nausea, somnolence, hypovolaemia, and electrolyte disturbances associated with cardiac arrhythmias and muscle spasms.</p><p><u>Treatment</u></p><p>The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms, stabilisation of the circulatory condition being of prime importance. If hypotension occurs, the patient should be placed in the supine position and salt and volume supplementation should be given rapidly. Valsartan cannot be eliminated by means of haemodialysis because of its strong plasma binding behaviour whereas clearance of hydrochlorothiazide will be achieved by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, valsartan and diuretics; ATC code: C09D A03.</p><p><u>Valsartan/hydrochlorothiazide </u></p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on hydrochlorothiazide 12.5 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (14.9/11.3 mmHg) compared to hydrochlorothiazide 12.5 mg (5.2/2.9 mmHg) and hydrochlorothiazide 25 mg (6.8/5.7 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (60%) compared to hydrochlorothiazide 12.5 mg (25%) and hydrochlorothiazide 25 mg (27%).</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on valsartan 80 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (9.8/8.2 mmHg) compared to valsartan 80 mg (3.9/5.1 mmHg) and valsartan 160 mg (6.5/6.2 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (51%) compared to valsartan 80 mg (36%) and valsartan 160 mg (37%).</p><p>In a double-blind, randomised, placebo-controlled, factorial design trial comparing various dose combinations of valsartan/hydrochlorothiazide to their respective components, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (16.5/11.8 mmHg) compared to placebo (1.9/4.1 mmHg) and both hydrochlorothiazide 12.5 mg (7.3/7.2 mmHg) and valsartan 80 mg (8.8/8.6 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (64%) compared to placebo (29%) and hydrochlorothiazide (41%).</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on hydrochlorothiazide 12.5 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/ hydrochlorothiazide 160/12.5 mg (12.4/7.5 mmHg) compared to hydrochlorothiazide 25 mg (5.6/2.1 mmHg). In addition, a significantly greater percentage of patients responded (BP &lt;140/90 mmHg or SBP reduction &ge;20 mmHg or DBP reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/12.5 mg (50%) compared to hydrochlorothiazide 25 mg (25%).</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on valsartan 160 mg, significantly greater mean systolic/diastolic BP reductions were observed with both the combination of valsartan/hydrochlorothiazide 160/25 mg (14.6/11.9 mmHg) and valsartan/hydrochlorothiazide 160/12.5 mg (12.4/10.4 mmHg) compared to valsartan 160 mg (8.7/8.8 mmHg). The difference in BP reductions between the 160/25 mg and 160/12.5 mg doses also reached statistical significance. In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/25 mg (68%) and 160/12.5 mg (62%) compared to valsartan 160 mg (49%).</p><p>In a double-blind, randomised, placebo-controlled, factorial design trial comparing various dose combinations of valsartan/hydrochlorothiazide to their respective components, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 160/12.5 mg (17.8/13.5 mmHg) and 160/25 mg (22.5/15.3 mmHg) compared to placebo (1.9/4.1 mmHg) and the respective monotherapies, i.e., hydrochlorothiazide 12.5 mg (7.3/7.2 mmHg), hydrochlorothiazide 25 mg (12.7/9.3 mmHg) and valsartan 160 mg (12.1/9.4 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/25 mg (81%) and valsartan/hydrochlorothiazide 160/12.5 mg (76%) compared to placebo (29%) and the respective monotherapies, i.e., hydrochlorothiazide 12.5 mg (41%), hydrochlorothiazide 25 mg (54%), and valsartan 160 mg (59%).</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on hydrochlorothiazide 12.5 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/ hydrochlorothiazide 160/12.5 mg (12.4/7.5 mmHg) compared to hydrochlorothiazide 25 mg (5.6/2.1 mmHg). In addition, a significantly greater percentage of patients responded (BP &lt;140/90 mmHg or SBP reduction &ge;20 mmHg or DBP reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/12.5 mg (50%) compared to hydrochlorothiazide 25 mg (25%).</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on valsartan 160 mg, significantly greater mean systolic/diastolic BP reductions were observed with both the combination of valsartan/hydrochlorothiazide 160/25 mg (14.6/11.9 mmHg) and valsartan/hydrochlorothiazide 160/12.5 mg (12.4/10.4 mmHg) compared to valsartan 160 mg (8.7/8.8 mmHg). The difference in BP reductions between the 160/25 mg and 160/12.5 mg doses also reached statistical significance. In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/25 mg (68%) and 160/12.5 mg (62%) compared to valsartan 160 mg (49%).</p><p>In a double-blind, randomised, placebo-controlled, factorial design trial comparing various dose combinations of valsartan/hydrochlorothiazide to their respective components, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 160/12.5 mg (17.8/13.5 mmHg) and 160/25 mg (22.5/15.3 mmHg) compared to placebo (1.9/4.1 mmHg) and the respective monotherapies, i.e., hydrochlorothiazide 12.5 mg (7.3/7.2 mmHg), hydrochlorothiazide 25 mg (12.7/9.3 mmHg) and valsartan 160 mg (12.1/9.4 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/25 mg (81%) and valsartan/hydrochlorothiazide 160/12.5 mg (76%) compared to placebo (29%) and the respective monotherapies, i.e., hydrochlorothiazide 12.5 mg (41%), hydrochlorothiazide 25 mg (54%), and valsartan 160 mg (59%).</p><p>Dose-dependent decreases in serum potassium occurred in controlled clinical studies with valsartan + hydrochlorothiazide. Reduction in serum potassium occurred more frequently in patients given 25 mg hydrochlorothiazide than in those given 12.5 mg hydrochlorothiazide. In controlled clinical trials with valsartan/hydrochlorothiazide the potassium lowering effect of hydrochlorothiazide was attenuated by the potassium-sparing effect of valsartan.</p><p>Beneficial effects of valsartan in combination with hydrochlorothiazide on cardiovascular mortality and morbidity are currently unknown. Epidemiological studies have shown that long-term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.</p><p>&nbsp;</p><p><u>Valsartan</u></p><p>Valsartan is an orally active and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor, which appears to counterbalance the effect of the AT1 receptor. Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000-fold) greater affinity for the AT1 receptor than for the AT2 receptor. Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p><p>Valsartan does not inhibit ACE, also known as kininase II, which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (P &lt;0.05) lower in patients treated with valsartan than in those treated with an ACE inhibitor (2.6% versus 7.9% respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide diuretic experienced cough compared to 68.5% of those treated with an ACE inhibitor (P &lt;0.05).</p><p>Administration of valsartan to patients with hypertension results in reduction of blood pressure without affecting pulse rate. In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4&ndash;6 hours. The antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the maximum reduction in blood pressure with any dose is generally attained within 2&ndash;4 weeks and is sustained during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved.</p><p>Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events.</p><p>In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80- 160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic patients (mean age: 58 years; 265 men) with microalbuminuria (valsartan: 58 &micro;g/min; amlodipine: 55.4 &micro;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 &micro;mol/l). At 24 weeks, UAE was reduced (p &lt;0.001) by 42% (&ndash;24.2 &micro;g/min; 95% CI: &ndash;40.4 to &ndash;19.1) with valsartan and approximately 3% (&ndash;1.7 &micro;g/min; 95% CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups. The Diovan Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102 &micro;g/min; 20&ndash; 700 &micro;g/min) and preserved renal function (mean serum creatinine = 80 &micro;mol/l). Patients were randomised to one of 3 doses of valsartan (160, 320 and 640 mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36% from baseline with valsartan 160 mg (95%CI: 22 to 47%), and by 44% with valsartan 320 mg (95%CI: 31 to 54 %). It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.</p><p>&nbsp;</p><p><u>Hydrochlorothiazide</u></p><p>The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na+Cl&macr; symporter perhaps by competing for the Cl&macr; site, thereby affecting electrolyte reabsorption mechanisms:directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly by this diuretic action reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium. The reninaldosterone link is mediated by angiotensin II, so with co-administration of valsartan the reduction in serum potassium is less pronounced as observed under monotherapy with hydrochlorothiazide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Valsartan/hydrochlorothiazide</u></p><p>The systemic availability of hydrochlorothiazide is reduced by about 30% when co-administered with valsartan. The kinetics of valsartan are not markedly affected by the co-administration of hydrochlorothiazide. This observed interaction has no impact on the combined use of valsartan and hydrochlorothiazide, since controlled clinical trials have shown a clear anti-hypertensive effect, greater than that obtained with either active substance given alone, or placebo.</p><p><u>Valsartan</u></p><p><em>Absorption </em></p><p>Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2&ndash;4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.</p><p><em>Distribution</em></p><p>The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94&ndash;97%), mainly serum albumin.</p><p><em>Biotransformation</em></p><p>Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.</p><p><em>Elimination</em></p><p>Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.</p><p><u>Hydrochlorothiazide</u></p><p><em>Absorption </em></p><p>The absorption of hydrochlorothiazide, after an oral dose, is rapid (tmax about 2 h), with similar absorption characteristics for both suspension and tablet formulations. Absolute bioavailability of hydrochlorothiazide is 60&ndash;80% after oral administration. Concomitant administration with food has been reported to both increase and decrease the systemic availability of hydrochlorothiazide compared with the fasted state. The magnitude of these effects is small and has minimal clinical importance. The increase in mean AUC is linear and dose proportional in the therapeutic range. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation is minimal when dosed once daily.</p><p><em>Distribution</em></p><p>The distribution and elimination kinetics have generally been described by a bi-exponential decay function. The apparent volume of distribution is 4&ndash;8 l/kg. Circulating hydrochlorothiazide is bound to serum proteins (40&ndash;70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at approximately 1.8 times the level in plasma.</p><p><em>Elimination</em></p><p>For hydrochlorotiazide, &gt;95% of the absorbed dose being excreted as unchanged compound in the urine. The renal clearance is composed of passive filtration and active secretion into the renal tubule. The terminal half-life is 6-15 h.</p><p><u><em>Special populations </em></u></p><p><em>Elderly</em></p><p>A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance. Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers.</p><p><em>Renal impairment</em></p><p>At the recommended dose of Co- Valista no dose adjustment is required for patients with a creatinine clearance of 30&ndash;70 ml/min. In patients with severe renal impairment (creatinine clearance &lt;30 ml/min) and patients undergoing dialysis no data are available for Co- Valista. Valsartan is highly bound to plasma protein and is not to be removed by dialysis, whereas clearance of hydrochlorothiazide will be achieved by dialysis.</p><p>Renal clearance of hydrochlorothiazide is composed of passive filtration and active secretion into the renal tubule. As expected for a compound which is cleared almost exclusively via the kidneys, renal function has a marked effect on the kinetics of hydrochlorothiazide (see section 4.3).</p><p><em>Hepatic impairment</em></p><p>In a pharmacokinetics trial in patients with mild (n=6) to moderate (n=5) hepatic dysfunction, exposure to valsartan was increased approximately 2-fold compared with healthy volunteers. There is no data available on the use of valsartan in patients with severe hepatic dysfunction (see section 4.3). Hepatic disease does not significantly affect the pharmacokinetics of hydrochlorothiazide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The potential toxicity of the valsartan - hydrochlorothiazide combination after oral administration was investigated in rats and marmosets in studies lasting up to six months. No findings emerged that would exclude the use of therapeutic doses in man.</p><p>The changes produced by the combination in the chronic toxicity studies are most likely to have been caused by the valsartan component. The toxicological target organ was the kidney, the reaction being more marked in the marmoset than the rat. The combination led to kidney damage (nephropathy with tubular basophilia, rises in plasma urea, plasma creatinine and serum potassium, increases in urine volume and urinary electrolytes from 30 mg/kg/day valsartan + 9 mg/kg/day hydrochlorothiazide in rats and 10 + 3 mg/kg/d in marmosets), probably by way of altered renal haemodynamics. These doses in rat, respectively, represent 0.9 and 3.5&ndash;times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. These doses in marmoset, respectively, represent 0.3 and 1.2&ndash;times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60kg patient.)</p><p>High doses of the valsartan - hydrochlorothiazide combination caused falls in red blood cell indices (red cell count, haemoglobin, haematocrit, from 100 + 31 mg/kg/d in rats and 30 + 9 mg/kg/d in marmosets). These doses in rat, respectively, represent 3.0 and 12 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. These doses in marmoset, respectively, represent 0.9 and 3.5 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient).</p><p>In marmosets, damage was observed in the gastric mucosa (from 30 + 9 mg/kg/d). The combination also led in the kidney to hyperplasia of the afferent aterioles (at 600 + 188 mg/kg/d in rats and from 30 + 9 mg/kg/d in marmosets). These doses in marmoset, respectively, represent 0.9 and 3.5 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. These doses in rat, respectively, represent 18 and 73 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient).</p><p>The above mentioned effects appear to be due to the pharmacological effects of high valsartan doses (blockade of angiotensin II-induced inhibition of renin release, with stimulation of the renin-producing cells) and also occur with ACE inhibitors. These findings appear to have no relevance to the use of therapeutic doses of valsartan in humans.</p><p>The valsartan - hydrochlorothiazide combination was not tested for mutagenicity, chromosomal breakage or carcinogenicity, since there is no evidence of interaction between the two substances. However, these tests were performed separately with valsartan and hydrochlorothiazide, and produced no evidence of mutagenicity, chromosomal breakage or carcinogenicity.</p><p>In rats, maternally toxic doses of valsartan (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient). Similar findings were seen with valsartan/hydrochlorothiazide in rats and rabbits. In embryo-fetal development (Segment II) studies with valsartan/hydrochlorothiazide in rat and rabbit, there was no evidence of teratogenicity; however, fetotoxicity associated with maternal toxicity was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cellulose, microcrystalline</p><p>Lactose monohydrate</p><p>Croscarmellose sodium</p><p>Povidone K29-32</p><p>Talc</p><p>Magnesium stearate</p><p>Silica, colloidal anhydrous</p><p><u>Film-coat</u></p><p>Polyvinyl alcohol</p><p>Talc</p><p>Titanium dioxide (E171)</p><p>Macrogol 3350</p><p>Lecithin (contains soya oil) (E322)</p><p>Iron oxide red (E172)</p><p>Iron oxide yellow (E172)</p><p>Iron oxide black (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in original pack to protect from moisture and heat.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC Al&nbsp;Blister and&nbsp;OPA/AL/PVC Blister</p><p>Pack sizes: 7, 14, 28, 30, 56, 98 and 280 tablets.</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2017.                                  
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>